Abstract
Overview
Introduction
The global Rheumatoid Arthritis (RA) market has experienced extraordinary
growth over the last decade. This market valued at $4.14 billion in 2004,
shows no hint of decline. The explosion in new disease modifying drugs since
the late 1990's has resulted in a competitive and rapidly evolving market.
However, the recent events in the COX-2 market will continue to impact all
arthritis drugs.
Scope
- Detailed analysis of traditional and biologic DMARDs, with sales and
volume forecasts to 2014 for the RA indication alone
- Assessment of current and future opportunities and threats in the RA
market across the seven major pharmaceutical markets
- Consideration of key events that may affect revenues in each of the seven
major pharmaceutical markets are applied and discussed
- Lifecycle management case studies show how previously successful
strategies should be applied in today's market
Report Highlights
The key indications required by a new disease-modifying treatment include
improvement in physical function, reducing signs and symptoms and inhibiting
structural progression. Additional indications in the treatment of early RA
and juvenile idiopathic arthritis would allow a new product to compete with
the now well-established TNF inhibitors.
The launch of new treatments at a premium cost appears to confer a superior
treatment, as exemplified by Abbott's launch of Humira. The variation in key
product pricing across different countries for a year of treatment shows that
careful selection of launch price is needed to make the product competitive
and also ensure good returns.
Japan, as the last market forecast to launch most of the biologics, lags
behind and is predicted to show slower uptake of these products. However, the
recent launch of Enbrel and forecast launch of Humira in this market is
expected to push the biologic class above traditional DMARDs by 2010 in this
region.
Reasons to Purchase
- Assess the impact of events such as Medicare changes, patent expiries and
sub-indication approvals on the RA sales of key brand name products
- Quantify the future size of the market, in terms of volume and value, for
the RA indication in each of the seven major markets
- Gain insight into opinion leaders thoughts on the challenges facing the RA
market
| 
View Cart
